AMPH vs UTHR
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. UTHR: United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing organ manufacturing innovation as a public benefit corporation.
Side-by-side fundamentals
| Metric | AMPH | UTHR | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $20.38 | $527.94 | |
| Market cap as of 2026-07-31 | $899M | $22.4B | |
| P/E as of 2026-07-31 | 12.22 | 17.29 | AMPH lower |
| PEG as of 2026-07-31 | -1.77 | 2.38 | AMPH lower |
| Net margin as of 2026-07-31 | +11.0% | +40.6% | UTHR higher |
| Gross margin as of 2026-07-31 | +47.3% | +86.6% | UTHR higher |
| Operating margin as of 2026-07-31 | +16.2% | +45.3% | UTHR higher |
| ROE as of 2026-07-31 | +10.2% | +19.2% | UTHR higher |
| ROA as of 2026-07-31 | +4.8% | +17.3% | UTHR higher |
| Debt / equity as of 2026-07-31 | 0.79 | 0.00 | UTHR lower |
| Revenue growth (YoY) as of 2026-07-31 | -1.4% | +5.9% | UTHR higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +18.0% | UTHR higher |
| Beta as of 2026-07-31 | 0.72 | 0.57 | |
| 1-year return as of 2026-07-30 close | -4.5% | +73.4% | UTHR higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.